METHOD DEVELOPMENT AND VALIDATION OF ULTRAVIOLET-VISIBLE SPECTROSCOPIC METHOD FOR THE ESTIMATION OF HEPATITIS-C DRUGS - DACLATASVIR AND SOFOSBUVIR IN ACTIVE PHARMACEUTICAL INGREDIENT FORM by Chakravarthy V, Ashok et al.
Vol 9, Suppl. 3, 2016
Online - 2455-3891 
Print - 0974-2441
METHOD DEVELOPMENT AND VALIDATION OF ULTRAVIOLET-VISIBLE SPECTROSCOPIC 
METHOD FOR THE ESTIMATION OF HEPATITIS-C DRUGS - DACLATASVIR AND SOFOSBUVIR 
IN ACTIVE PHARMACEUTICAL INGREDIENT FORM
ASHOK CHAKRAVARTHY V1*, SAILAJA BBV1, PRAVEEN KUMAR A2
1Department of Inorganic and Analytical Chemistry, Andhra University, Vishakhapatnam - 530003, Andhra Pradesh, India. 2Department of 
Chemistry, Changwon National University, Changwon 641773, Korea. Email: mykingsenglish@gmail.com
Received: 10 August 2016, Revised and Accepted: 16 August 2016
ABSTRACT
Objective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitative 
estimation of hepatitis-C drugs - Daclatasvir and Sofosbuvir in its active pharmaceutical ingredient (API) form.
Methods: The developed ultraviolet spectrophotometric method for the quantitative estimation of hepatitis-C drugs - Daclatasvir and Sofosbuvir is 
based on measurement of absorption at a wavelength maximum (λmax) of 317 and 261 nm using methanol as solvent.
Results: The method was validated in terms of specificity, precision, linearity, accuracy, and robustness as per the ICH guidelines. The method was 
found to be linear in the range of 50-150% for Daclatasvir and in the range of 43-143% for Sofosbuvir. The percentage recovery values were in the 
range of 99.4-100.6% for Daclatasvir and in the range of 99.7-100.6% for Sofosbuvir at different concentration levels. Relative standard deviation for 
precision and intermediate precision results were found to be <2%. The correlation coefficient value observed for Daclatasvir and Sofosbuvir drug 
substances was not <0.99, 0.99, respectively. Results obtained from the validation experiments prove that the developed method is quantified for the 
estimation of Daclatasvir and Sofosbuvir drug substances.
Conclusion: The developed method can be successfully applied for routine analysis, quality control analysis, and also suitable for stability analysis of 
Daclatasvir and Sofosbuvir in API form as per the regulatory requirements.
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INTRODUCTION




dihydrochloride, and this drug is used for the treatment of hepatitis-C 
virus (HCV) infection [1,2]. Daclatasvir is a chiral molecule with four 
stereocenters (1, 1’, 2, 2) in the S configuration. Daclatasvir is a white to 
yellow crystalline non-hygroscopic powder. It is freely soluble in water, 
dimethyl sulfoxide, and methanol; soluble in ethanol (95%); practically 
insoluble in dichloromethane, tetrahydrofuran, acetonitrile, acetone, 
and ethyl acetate [2]. Daclatasvir structure is shown in Fig. 1.
Daclatasvir is a first in class direct acting antiviral agent which binds 
to and inhibits the function of the HCV protein NS5A. NS5A is involved 
in both viral RNA replication and virus particle assembly. A putative 
inhibitor-binding region spanning amino acids 21-30 of NS5A was 
identified [2].
The goal of antiviral therapy against HCV is to reach sustained 
virological response (SVR), which is traditionally defined as the 
absence of quantifiable virus in plasma at least 24 weeks after the end 
of therapy. However, most relapses occur within 4 weeks of treatment 
discontinuation, and a 98-99% concordance has been shown between 
absence of quantifiable virus 12 weeks after therapy and SVR24. 
Therefore, the absence of measurable virus 12 weeks post end of 
treatment (SVR12) is presently accepted by European and the US 
regulators as the primary endpoint in clinical trials [2].
The chemical name of Sofosbuvir is Isopropyl (2S)-2-[[[(2R,3R,4R,5R)-
5-(2,4-dioxopyrimidin-1-yl)-4-f luoro-3-hydroxy-4-methyl-
tetrahydrofuran-2-yl]methoxy-phenoxy- phosphoryl] amino] 
propanoate. Sofosbuvir is a nucleotide analog used in combination with 
other drugs for the treatment of HCV infection. It has been marketed 
since 2013. Compared to previous treatments, Sofosbuvir-based 
regimens provide a higher cure rate, fewer side effects, and a 2- to 4-fold 
reduced duration of therapy. Sofosbuvir allows most patients to be 
treated successfully without the use of pegylated interferon (pegIFN), 
an injectable drug with severe side effects that is a key component 
of older drug combinations for the treatment of HCV. Sofosbuvir 
inhibits the RNA polymerase that the HCV uses to replicate its RNA. It 
was discovered at Pharmasset and developed by Gilead Sciences [3]. 
Sofosbuvir structure is shown in Fig. 2.
In 2013, the FDA approved Sofosbuvir in combination with ribavirin 
(RBV) for oral dual therapy of HCV genotypes 2 and 3 and for triple 
therapy with injected pegIFN and RBV for treatment-naive patients with 
HCV genotypes 1 and 4. In 2014, a combination of Sofosbuvir with the 
viral NS5A inhibitor ledipasvir was approved. This latter combination 
provides high cure rates in people infected with genotype 1 (the most 
common subtype in the U.S., Japan, and much of Europe) without the use 
of IFN, irrespective of prior treatment failure, or the presence of cirrhosis. 
In September 2014, Gilead announced that it was proposing generic 
licensing agreements with manufacturers in 91 developing countries to 
produce and sell Sofosbuvir, and that it would sell a name brand version 
of the product in India for approximately $300 per course of treatment. 
It is on the World Health Organization’s List of Essential Medicines, a list 
of the most important medications needed in a basic health system [3].
Sofosbuvir is a white to off-white crystalline solid and is slightly soluble 
in water [4] with a solubility of ≥2 mg/mL across the pH range of 2-7.7 
at 37°C [5]. Water solubility of 0.824 mg/mL and pKa value of 9.3 was 
reported [6]. Sofosbuvir is freely soluble in ethanol [7].
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From the literature survey, it is evident that very few research articles 
are available for Daclatasvir and Sofosbuvir. Sundaram and Kowdley 
published an article on dual Daclatasvir and Sofosbuvir for the treatment 
of genotype 3 chronic HCV infection [8]. Bunchorntavakul and Reddy 
published a review article on the efficacy and safety of Daclatasvir in the 
treatment of chronic HCV infection [9]. Ashok and Sailaja published an 
article on method development and validation of assay and dissolution 
methods for the estimation of Daclatasvir in tablet dosage forms by 
reverse phase high-performance liquid chromatography (HPLC) [10]. 
Shi et al. published an article on evaluation of a rapid method for the 
simultaneous quantification of RBV, Sofosbuvir, and its metabolite 
in rat plasma by ultra-performance liquid chromatography tandem 
mass spectrometry (UPLC-MS/MS) [11]. Debasish et al. published an 
article on the characterization of forced degradation products and 
in silico toxicity prediction of Sofosbuvir: A novel HCV NS5B polymerase 
inhibitor [12]. Pan et al. published an article on the simultaneous 
determination of Ledipasvir, Sofosbuvir, and its metabolite in rat 
plasma by UPLC-MS/MS and its application to a pharmacokinetic 
study [13]. Rezk et al. published an article on the development of a 
sensitive UPLC-ESI-MS/MS method for quantification of Sofosbuvir 
and its metabolite, GS-331007, in human plasma: Application to a 
bioequivalence study [14].
Analytical methods are not available in USP [15] and European 
Pharmacopoeia [16] for the quantitative determination of 
Daclatasvir and Sofosbuvir drugs. The present research work 
describes the estimation of assay content of Daclatasvir and 
Sofosbuvir in active pharmaceutical ingredient (API) form using 
ultraviolet-visible (UV-vis) spectrophotometry technique. The 
work gives a sensitive, specific, and economical method for the 
determination of Daclatasvir and Sofosbuvir in very short time by 
the UV-vis spectrophotometer. Methanol is used as a solvent for 
diluent preparation based on the drug solubility properties of both 
Daclatasvir and Sofosbuvir. Developed UV-vis spectrophotometric 




Qualified standards (Daclatasvir purity ∼99.3%, Sofosbuvir ∼99.9) and 
samples are obtained from Natco Pharma Limited and Hetero Drugs 
Limited and were used without any further purification. HPLC grade 
methanol (MeOH purity ∼99.8%) was obtained from Rankem (Mumbai, 
India).
Instrumentation
A double beam UV-vis spectrophotometer (Shimadzu, model 1800) 
having two matched quartz cells with 1 cm light path length and 
loaded with UV probe software was used for recording of spectra and 
measuring absorbance for method development and validation study.
Method development
Selection of diluent
Methanol was used as diluent for the preparation of standards and 
samples for Daclatasvir and Sofosbuvir API’s based on the solubility 
characteristics of both the drug substances.
Selection of suitable wavelength detection
Spectra for Daclatasvir and Sofosbuvir were measured from 200 to 
800 nm for wavelength maxima by recording UV-vis spectrum of 
standard solution. The corresponding spectrum of Daclatasvir and 
Sofosbuvir is shown in Figs. 3 and 4. Maximum absorbance (λmax) was 
shown at 317 and 261 nm for standard solution of Daclatasvir and 
Sofosbuvir. Based on the spectra maxima, 317 and 261 nm were selected 
for identification and quantification of Daclatasvir and Sofosbuvir drugs.
Preparation of standard and sample solutions for Daclatasvir
Standard stock solution of Daclatasvir
Accurately weighed and transferred 50 mg of Daclatasvir working 
standard into a 50 ml volumetric flask. Added about 30 ml of diluent 
and sonicated to dissolve with intermittent shaking. The resulting 
solution is diluted up to the mark with diluent and mixed well.
Preparation of standard solution
Transferred 0.4 ml of Daclatasvir standard stock solution into a 50 ml 
volumetric flask and diluted up to the mark with the diluent and mixed 
well.
Preparation of sample solution
Accurately weighed and transferred 50 mg of Daclatasvir drug substance 
into a 50 ml volumetric flask. Added about 30 ml of diluent and sonicated 
to dissolve with intermittent shaking. The resulting solution is diluted 
up to the mark with diluent and mixed well. Further, diluted 0.4 ml of 
Daclatasvir sample stock solution into a 50 ml volumetric flask and 
diluted up to the mark with the diluent and mixed well and transferred 
the resultant sample solution into UV cuvettes for analysis.
Preparation of standard and sample solutions for Sofosbuvir
Standard stock solution of Sofosbuvir
Accurately weighed and transferred 50 mg of Sofosbuvir working 
standard into a 50 ml volumetric flask. Added about 30 ml of diluent 
Fig. 1: Structure of Daclatasvir dihydrochloride
Fig. 2: Structure of Sofosbuvir
Asian J Pharm Clin Res, Vol 9, Suppl. 3, 2016, 61-66
 Ashok et al. 
63
and sonicated to dissolve with intermittent shaking. The resulting 
solution is diluted up to the mark with diluent and mixed well.
Preparation of standard solution
Transferred 0.7 ml of Sofosbuvir standard stock solution into a 25 ml 
volumetric flask and diluted up to the mark with the diluent and mixed 
well.
Preparation of sample solution
Accurately weighed and transferred 50 mg of Sofosbuvir drug 
substance into a 50 ml volumetric flask. Added about 30 ml of diluent 
and sonicated to dissolve with intermittent shaking. The resulting 
solution is diluted up to the mark with diluent and mixed well. 
Further, diluted 0.7 ml of Sofosbuvir sample stock solution into a 25 ml 
volumetric flask and diluted up to the mark with the diluent and mixed 




Specificity is the ability to assess unequivocally the analyte in the 
presence of components which may be expected to be present. 
Typically these might include impurities, degradants, and matrix [17]. 
The specificity of the developed method was established to prove 
the absence of interference from diluent absorbance which is part of 
required pharmaceutical drug substance preparation.
Linearity
Linearity is the ability of the method to obtain results which are 
either directly or after mathematical transformation proportional to 
the concentration of the analyte within a given range. The linearity of 
response for Daclatasvir and Sofosbuvir was determined in the range 
from 50% to 150% for Daclatasvir and in the range of 43-143% for 
Sofosbuvir. The five concentrations of each component were subjected 
to regression analysis by least squares method to calculate correlation 
coefficient and calibration equation. The method of linear regression 
was used for the data evaluation.
Precision
Precision is a measure of the reproducibility of the whole analytical 
method under normal operating conditions. The precision was 
expressed as the relative standard deviation (RSD).
% RSD = (Standard deviation/average) × 100
The precision of the developed method was carried out by six 
determinations (preparations) of the test solution by measuring the 
absorbance of test solution and calculated the % RSD for estimation of 
drug content.
Accuracy
Accuracy or trueness was determined by applying the method to 
samples, in which known amounts of analyte have been added. These 
should be analyzed against standard and blank solutions to ensure that 
no interference exists. The accuracy was calculated from the test results 
as a percentage of the analyte recovered by the assay.
The accuracy of the present method was carried out using the drug 
substance spiked solution at three different concentration levels of 50%, 
100%, and 150% for Daclatasvir and 43%, 100%, and 143% for Sofosbuvir, 
in triplicate determinations. Percent recovery and the mean percentage 
recovery were calculated for Daclatasvir and Sofosbuvir drug substances.
Robustness
Robustness of the method indicates the reliability of analysis to 
assess the system suitability parameters under the influence of 
small but deliberate variations in method parameters. Robustness 
was performed by changing the detection wavelength ±2 nm to the 
wavelength maximum (λmax) and calculating the % assay and % RSD for 
the test solution.
Solution stability
Daclatasvir and Sofosbuvir sample solutions and the standard solutions 
were prepared as per the test procedure. All these solutions were 
divided into two portions. One portion was stored at room temperature, 
and the other portion was stored in the refrigerator at 2-8°C. Freshly 
prepared solutions and the solutions, which were stored at room 
temperature and in refrigerator (2-8°C) up to 24 hrs, were measured for 
absorbance at different time intervals. The % assay obtained at initial 
was compared with the % assay obtained at different time intervals.
RESULTS AND DISCUSSION
Optimization of UV-vis spectrophotometric method conditions
The main purpose of the current method is to develop a simple, sensitive, 
and precise UV-vis spectrophotometric method for the estimation of 
Fig. 3: Daclatasvir standard spectrum
Fig. 4: Sofosbuvir standard spectrum
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Daclatasvir and Sofosbuvir for the routine quantitative determination of 
samples which will reduce tedious sample preparations, cost of materials 
and manpower required to perform the analysis. Daclatasvir and 
Sofosbuvir are UV-absorbing molecules with specific chromophores in 
the structure that absorb at a particular wavelength, and this absorbance 
was successfully employed for their quantitative determinations using 
the UV spectroscopic method. The spectral analysis showed that the λmax 
of Daclatasvir and Sofosbuvir are 317 and 261 nm, respectively. Simple 
diluent methanol was selected for the standard and sample solutions of 
Daclatasvir and Sofosbuvir drug substances. Thus, the developed UV-vis 
spectroscopic method for the analysis of Daclatasvir and Sofosbuvir in 
its API form enables analysis of several samples at the same time due to 
its simplicity in performing the analysis.
The UV-vis spectra of blank run, Daclatasvir standard solution 
(concentration - 8 µg/mL), Daclatasvir sample solution (concentration - 
8 µg/mL), Sofosbuvir standard solution (concentration - 28 µg/mL), 
and Sofosbuvir sample solution (concentration - 28 µg/mL) are shown 
in Figs. 3-7.
Method validation
The objective of validation of an analytical procedure is to demonstrate that 
it is suitable for its intended use. The described UV-vis spectrophotometric 
method for the estimation of Daclatasvir and Sofosbuvir has been 
extensively validated for identification and quantification of its drug 
substances as per ICH guidelines [17]. After successful completion 
of method development [10,18], method validation [17,19-21] was 
performed to ensure that the developed method was capable of giving 
reproducible and reliable results when used by different operators 
employed on the same equipment of the same laboratory or different 
laboratories. The developed UV-vis spectrophotometric method was 
validated to quantify Daclatasvir and Sofosbuvir in its API form by 
determining the parameters including specificity, precision, linearity, 
accuracy, and robustness according to the ICH guidelines.
Specificity
Specificity of the developed method was performed by scanning the UV-
vis spectra of diluent, standard, and sample solutions of Daclatasvir and 
Sofosbuvir from 200 to 800 nm. Furthermore, spectral homogeneity of 
Daclatasvir and Sofosbuvir control samples found to be similar with 
those obtained for the standard solutions of Daclatasvir and Sofosbuvir.
Precision
Method precision was determined by analyzing the test solution of 
six determinations, and the observed values of % RSD were shown 
in Table 1. % RSD for Daclatasvir and Sofosbuvir compounds in test 
Fig. 5: Blank spectrum
Fig. 6: Daclatasvir sample spectrum
Fig. 7: Sofosbuvir sample spectrum
Fig. 8: Linearity graph of Daclatasvir
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solution for six determinations was not more than 2.0%. Intermediate 
precision of the method was studied by analyzing the test solution of 
six determinations, and the observed results were shown in Table 1. 
The % RSD difference between the two analysts is 0.15% and 0.09% for 
Daclatasvir and Sofosbuvir, respectively. Less difference between the 
two analysts shows that the developed method is precise and has good 
intermediate precision.
Linearity
The linearity graphs were plotted between the absorbance versus 
concentration to obtain the calibration curve. Linearity graphs for 
Daclatasvir and Sofosbuvir were shown in Figs. 8 and 9. The response 
obtained for Daclatasvir and Sofosbuvir was found to be linear from 50% 
to 150% and 43% to 143% of standard concentration. The correlation 
coefficient observed for Daclatasvir and Sofosbuvir compounds was not 
<0.99 and also statistical values of all compounds were shown in Table 2. 
Results demonstrate that an excellent correlation between the absorbance 
and concentration of Daclatasvir and Sofosbuvir drug substances.
Accuracy
The percentage recovery results for Daclatasvir and Sofosbuvir were 
varied from 99.4% to 100.6% and 99.7% to 100.6% at three different 
concentration levels, and the results were shown in Table 3. Based on the 
% recovery data, it was concluded that the developed method is capable 
for the estimation of Daclatasvir and Sofosbuvir drug substances and is 
adequate for routine analysis.
Robustness
The robustness of the proposed method was performed by preparing 
the standard solutions and test solutions of Daclatasvir and Sofosbuvir 
at 100% level were analyzed by a change in wavelength for absorbance 
readings. The wavelength selected was ±2 nm to the λmax, i.e., 315 and 
319 nm for Daclatasvir drug and 259 and 263 nm for Sofosbuvir drug, 
respectively, for standard and sample solutions. In the robustness 
condition (wavelength variation of ±2 nm to the λmax), the assay values 
of Daclatasvir and Sofosbuvir were not <99%. % Assay results for 
robustness parameters were shown in Table 4.
Solution stability
The percent assay value difference was determined for solutions stored 
at room temperature and at refrigerated condition (2-8°C) for different 
time intervals up to 24 hrs. Daclatasvir and Sofosbuvir absorbances 
were found to be stable up to 24 hrs at room temperature and also at 
refrigerator condition. Solution stability results at room temperature 
and refrigerated condition were shown in Table 5.
CONCLUSIONS
Simple, precise, and economical UV-vis spectrophotometric method 
has been developed for the quantitative estimation of Daclatasvir and 
Sofosbuvir in its API form. Method is validated as per the ICH guidelines 
and also the developed method is robust with respect to wavelength 
Table 1: Precision and intermediate precision data
Determination (% Assay)
For Daclatasvir For Sofosbuvir
Method precision Intermediate precision Method precision Intermediate precision
Determination-1 100.2 99.5 100.1 100.0
Determination-2 99.7 99.6 99.9 100.4
Determination-3 99.5 99.7 100.0 99.7
Determination-4 99.4 99.3 100.2 99.8
Determination-5 99.5 99.6 99.8 99.7
Determination-6 99.3 99.7 100.0 99.8
Average 99.6 99.6 100.0 99.9
SD 0.32 0.17 0.17 0.26
% RSD 0.32 0.17 0.17 0.26
SD: Standard deviation, RSD: Relative standard deviation
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50 99.6-100.3 43 99.7-100.6
100 99.4-99.8 100 99.8-100.2
150 99.9-100.6 143 99.7-99.9
Table 4: Robustness results
Determination % Assay of 
Daclatasvir 
at 315 nm
% Assay of 
Daclatasvir 
at 319 nm
% Assay of 
Sofosbuvir 
at 259 nm
% Assay of 
Sofosbuvir 
at 263 nm
Determination-1 99.5 99.5 99.9 99.9
Determination-2 99.3 99.3 99.9 100.1
Determination-3 99.4 99.4 100.0 99.9
Average 99.4 99.4 100.0 100.0
SD 0.11 0.11 0.08 0.12
%RSD 0.11 0.12 0.08 0.12
SD: Standard deviation, RSD: Relative standard deviation
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variation to the original wavelength. The developed method can be used 
for the quantification of Daclatasvir and Sofosbuvir drug substances in 
routine analysis.
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% Assay of standard solution at RT 99.9 99.7 99.7 99.5 0.4
% Assay of sample solution at RT 100.2 100.0 99.8 99.7 0.5
% Assay of standard solution at 2-8°C 99.9 99.9 99.5 99.3 0.6
% Assay of sample solution at 2-8°C 100.2 99.8 99.7 99.5 0.7
Sofosbuvir solution stability
% Assay of standard solution at RT 100.0 99.8 99.6 99.6 0.4
% Assay of sample solution at RT 100.1 100.1 99.9 99.7 0.4
% Assay of standard solution at 2-8°C 100.0 99.8 99.6 99.8 0.4
% Assay of sample solution at 2-8°C 100.1 99.9 99.7 99.5 0.6
RT: Room temperature
